387 results match your criteria: ""S.G.Moscati" Hospital[Affiliation]"

New approach to implement cancer patient care: The valutazione percorso rete oncologica campana (ValPeROC)-experience from an Italian oncology network.

Eur J Cancer Care (Engl)

November 2022

Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy.

Objective: The primary goal of the Campania Oncology Network (ROC) was to reduce cancer delay and care fragmentation through the establishment of cancer-specific multidisciplinary oncologic groups (GOMs) and diagnostic and therapeutic assistance paths (PDTAs).

Methods: Five cancer centres of the ROC, with their own cancer specific GOM, were selected. In our analysis, we have focused on four neoplasms: lung, colon, ovarian and prostate cancers.

View Article and Find Full Text PDF

TKIs long-term treatment in CML may lead to persistent adverse events (AEs) that can promote relevant morbidity and mortality. Consequently, TKIs dose reduction is often used to prevent AEs. However, data on its impact on successful treatment-free remission (TFR) are quite scarce.

View Article and Find Full Text PDF

Mast Cell Leukemia: An Update with a Practical Review.

Cancers (Basel)

March 2023

Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy.

Mast cell leukemia (MCL) is the leukemic form of SM with at least 20% mostly immature mast cells on bone marrow aspirate. MCL may develop de novo, in the absence of a prior SM, or it may represent a progression from a previous SM. MCL may be sub-divided into the more frequent, aggressive acute form with signs of organ damage (C-findings) and the chronic form lacking C-findings and presenting a more stable course, although over time, progression to acute MCL is common.

View Article and Find Full Text PDF

Background: The use of immune checkpoint inhibitors (ICIs) in the front-line treatment of advanced non-small-cell lung cancer (NSCLC) is currently the standard of care. However, as clinical trials include a very limited number of elderly patients, evidence on the safety and efficacy of using ICI-based regimens is still limited.

Methods: A virtual International Expert Panel took place in July 2022 to review the available evidence on the use of ICI-based regimens in the first-line setting in elderly patients with NSCLC and provide a position paper on the field both in clinical practice and in a research setting.

View Article and Find Full Text PDF
Article Synopsis
  • CTLA-4/PD-1/PD-L1 immune checkpoint inhibitors are standard treatments for advanced non-small cell lung cancer (NSCLC), but new monoclonal antibodies are emerging as potential therapies.
  • The paper aims to review both recently approved and emerging monoclonal antibody immune checkpoint inhibitors for NSCLC treatment.
  • More extensive studies and phase III trials are necessary to better understand the effectiveness of new ICIs and how they interact with the tumor microenvironment and patient selection.
View Article and Find Full Text PDF

RET-selective tyrosine kinase inhibitors (TKIs) selpercatinib and pralsetinib have revolutionized the landscape of RET-positive (RET+) advanced non-small cell lung cancer (NSCLC) treatment, thanks to their efficacy and safety profiles. This class of medications currently represents the standard of care for both naïve and patients that have not received selective RET-TKIs in the first-line setting. However, we presently lack a satisfactory understanding of resistance mechanism developing after selective RET-TKIs usage, as well as a specific treatment for patients progressing on selpercatinib or pralsetinib.

View Article and Find Full Text PDF

Excess Absorbance as a Novel Approach for Studying the Self-Aggregation of Vital Dyes in Liquid Solution.

Int J Mol Sci

January 2023

Department of Medicine and Health Sciences "V. Tiberio", University of Molise, Via F. De Sanctis, 86100 Campobasso, Italy.

In the present paper, a simple method for analyzing the self-aggregation of dyes in a solution by a UV-visible absorption measurements is proposed. The concept of excess absorbance is introduced to determine an equation whose coefficients determine the parameters of the aggregation equilibrium. The computational peculiarities of the model are first discussed theoretically and then applied to sodium fluorescein in polar protic and aprotic solvents, as well as in aqueous solutions of methylene blue, which is a cationic dye.

View Article and Find Full Text PDF
Article Synopsis
  • Only two antiangiogenic monoclonal antibodies combined with EGFR-TKIs (erlotinib + bevacizumab and erlotinib + ramucirumab) are currently approved for treating EGFR+ advanced non-small cell lung cancer.
  • Patients eventually develop resistance to these treatments due to mechanisms like T790M substitutions and MET amplifications.
  • Osimertinib is the only approved option for T790M+ patients, but emerging data suggests MET-TKIs and combinations with chemotherapy/immunotherapy could improve treatment strategies in the future.
View Article and Find Full Text PDF

Background: Nivolumab is the first programmed cell death receptor 1 (PD-1) inhibitor approved in China. Compared with chemotherapy, nivolumab has shown advantages of good efficacy and safety in the treatment of a variety of tumors. However, due to its short time of use in China and lack of safety experience, clinical understanding of its adverse reactions has not been sufficiently elucidated.

View Article and Find Full Text PDF

The Secret behind Extreme Hypoxia Tolerance: A "Slow-Growth" Thoracoabdominal Aneurysm.

Aorta (Stamford)

December 2022

Division of Cardiac Surgery, Department of Cardiovascular Surgery, S.G. Moscati Hospital, Avellino, Italy.

A 61-year-old man presented to our institution complaining of back pain. Breathing was comfortable. An arterial blood gas showed extreme hypoxia causing chronic respiratory alkalosis.

View Article and Find Full Text PDF

Periprosthetic fractures around total knee arthroplasty in elderly represent an emerging cause of implant revision and their incidence seems destined to further increase in the upcoming years, considering the ever-increasing number of implanted prostheses. These are complex injuries with very high complication rates. It has been estimated that the incidence of femoral periprosthetic fractures after T.

View Article and Find Full Text PDF

Background: Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor with demonstrated efficacy in locally advanced and metastatic non-small cell lung cancer (NSCLC) in crizotinib-refractory and ALK inhibitor-naive settings. This analysis assessed brigatinib in Asian vs. non-Asian patients from the first-line ALTA-1L trial.

View Article and Find Full Text PDF

Endocrine disruptive potential of inhaled particulate matter.

J Hazard Mater

September 2022

Department of Medicine, Surgery and Dentistry "Schola Medica Salernitana", University of Salerno, Baronissi, Italy. Electronic address:

View Article and Find Full Text PDF

Expert consensus on perioperative treatment for non-small cell lung cancer.

Transl Lung Cancer Res

July 2022

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

View Article and Find Full Text PDF
Article Synopsis
  • Immune-checkpoint inhibitors (ICIs) are improving treatment options for patients with advanced stage non-small cell lung cancer (NSCLC), but their effectiveness in oncogene-addicted cases is still under debate.
  • The study analyzed 167 PD-L1 positive NSCLC patients to explore the presence of genomic alterations in five driver oncogenes.
  • Findings revealed that over half of the patients had genomic alterations, and despite these alterations, 37.5% of patients with high PD-L1 expression showed clinical benefit from ICIs.
View Article and Find Full Text PDF

A novel phenotype in an Italian family with a rare progranulin mutation.

J Neurol

November 2022

Center for Neurodegenerative Diseases (CEMAND), Department of Medicine, Surgery and Odontology "Scuola Medica Salernitana", University of Salerno, Salerno, Italy.

Introduction: Progranulin (PGRN) is a secreted glycoprotein encoded in humans by the GRN gene, located on chromosome 17q21. Several nonsense and missense pathogenetic GRN mutations have been described.

Objective: We herein describe two sisters carrying a rare GRN mutation with extremely different clinical features and family history of dementia and behavioral disorders, with a novel presentation with stridor and dysphonia.

View Article and Find Full Text PDF
Article Synopsis
  • The genetic nature of cancer highlights the importance of molecular diagnoses and personalized treatments, especially for non-small cell lung cancer (NSCLC) patients with prevalent KRAS mutations, particularly KRAS G12C.
  • Sotorasib is noted as the first approved drug specifically targeting KRAS G12C mutations, providing significant clinical benefits for previously treated NSCLC patients.
  • Ongoing research focuses on overcoming resistance to KRAS inhibitors and exploring their effectiveness in combination with other therapies to enhance treatment outcomes for NSCLC patients with KRAS mutations.
View Article and Find Full Text PDF

, ,  and gene fusions and exon 14 skipping alterations represent novel predictive biomarkers for advanced non-small-cell lung cancer (NSCLC). Therefore, testing patients for these genetic variants is crucial for choosing the best selective treatment. Over the last couple of decades, next-generation sequencing (NGS) platforms have emerged as an extremely useful tool for detecting these variants.

View Article and Find Full Text PDF

In recent years, stereotactic body radiation therapy (SBRT) has gained popularity among clinical methods for the treatment of medium and low risk prostate cancer (PCa), mainly as an alternative to surgery. The hypo-fractionated regimen allows the administration of high doses of radiation in a small number of fractions; such a fractionation is possible by exploiting the different intrinsic prostate radiosensitivity compared with the surrounding healthy tissues. In addition, SBRT treatment guaranteed a better quality of life compared with surgery, avoiding risks, aftermaths, and possible complications.

View Article and Find Full Text PDF

The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM). The present study is a 3-year follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloRd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers.

View Article and Find Full Text PDF

In infants and children, fever is very common in the emergency setting. The overall aim of the present publication was to overview guidance and provide an algorithm for use in the emergency setting as well as recommendations to inform parents for home care. To obtain consensus, a core steering committee drafted a management algorithm and general consensus was obtained by remote voting among experts.

View Article and Find Full Text PDF